Ranbaxy Pharmaceuticals Inc., a wholly owned subsidiary of Ranbaxy Laboratories Ltd., has launched an authorized generic version of Caduet in the US market, as part of an agreement with Pfizer Inc.
Caduet is a fixed-dose combination of atorvastatin-amlodipine besylate (presently marketed by Pfizer under the brand Caduet, which also contains a crystalline form of atorvastatin). The product is indicated for patients suffering from both, high blood pressure and high levels of cholesterol. Caduet generated total annual sales of $339 million in the US (IMS – MAT September 2011).